The Groningen spinout is developing antibiotics that could help overcome increasing bacterial resistance to existing drugs.

AgileBiotics, a Netherlands-based antibiotics developer spun out from University of Groningen, has raised an undisclosed amount of funding from commercialisation firm Carduso Capital.

Carduso Capital manages a $35m fund called Carduso Capital Groningen NL for tech transfer from University of Groningen and University Medical Center Groningen. The fund was not, however, named explicitly in the press release.

Founded in 2017, AgileBiotics has developed an antibiotics creation platform called OxaSelect that facilitates the modification of existing compounds to build new antibiotics more quickly and cost-effectively than traditional…